The global burden of acne increased from 1990 to 2023, according to a new analysis of international health data — a finding that reframes a condition often dismissed as a teenage rite of passage.

The study spans 33 years and covers the full 1990–2023 window, positioning acne as a growing rather than shrinking problem for dermatology at a time when much of the field's attention and investment has flowed toward psoriasis, eczema and skin cancer.

Why does a rise over 33 years matter?

Acne is already one of the most common dermatologic conditions on earth, and prevalence of that magnitude means even small percentage shifts translate into enormous absolute numbers of patients. A rising burden curve across 1990–2023 tells clinicians, payers and drug developers that demand for acne care is moving in one direction.

It also runs counter to the casual assumption that acne is self-limiting and clinically minor. Burden measures — the metric this analysis tracks — capture not just case counts but the aggregate weight a condition places on populations over time.

What does this change for dermatology?

For practicing dermatologists, the practical question is capacity. A steadily increasing global burden means more patients presenting for acne care, more follow-up management for a chronic-recurrent condition, and sustained pressure on access to treatments — from topical retinoids to systemic therapies — across health systems.

For researchers and manufacturers, a 33-year upward trend strengthens the case that acne deserves the same rigor in epidemiologic tracking that chronic inflammatory skin diseases receive. Rising burden in a condition concentrated in adolescents and young adults also carries implications beyond the skin, given acne's documented association with quality-of-life impairment during formative years.

What comes next

Whether the trajectory continues past 2023 will depend on the next round of global estimates — but for now, the data confirms that acne's burden grew, not shrank, across three decades.